Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 24
Filtrar
Más filtros

País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Mar Drugs ; 20(11)2022 Oct 28.
Artículo en Inglés | MEDLINE | ID: mdl-36354999

RESUMEN

Acute and chronic dermatological injuries need rapid tissue repair due to the susceptibility to infections. To effectively promote cutaneous wound recovery, it is essential to develop safe, low-cost, and affordable regenerative tools. Therefore, we aimed to identify the biological mechanisms involved in the wound healing properties of the glycosaminoglycan dermatan sulfate (DS), obtained from ascidian Styela plicata, a marine invertebrate, which in preliminary work from our group showed no toxicity and promoted a remarkable fibroblast proliferation and migration. In this study, 2,4-DS (50 µg/mL)-treated and control groups had the relative gene expression of 84 genes participating in the healing pathway evaluated. The results showed that 57% of the genes were overexpressed during treatment, 16% were underexpressed, and 9.52% were not detected. In silico analysis of metabolic interactions exhibited overexpression of genes related to: extracellular matrix organization, hemostasis, secretion of inflammatory mediators, and regulation of insulin-like growth factor transport and uptake. Furthermore, in C57BL/6 mice subjected to experimental wounds treated with 0.25% 2,4-DS, the histological parameters demonstrated a great capacity for vascular recovery. Additionally, this study confirmed that DS is a potent inducer of wound-healing cellular pathways and a promoter of neovascularization, being a natural ally in the tissue regeneration strategy.


Asunto(s)
Dermatán Sulfato , Urocordados , Animales , Ratones , Dermatán Sulfato/metabolismo , Dermatán Sulfato/farmacología , Ratones Endogámicos C57BL , Urocordados/metabolismo , Cicatrización de Heridas , Recursos Naturales
2.
Public Health ; 180: 29-37, 2020 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-31838343

RESUMEN

OBJECTIVES: This study aimed to assess the impact of the latest smoke-free legislation on hospital admission rates due to smoking-related diseases in Spain. STUDY DESIGN: A retrospective cohort study was conducted to evaluate changes in hospital admission rates for cardiovascular, respiratory diseases, and smoking-related cancer in Valencia, Spain, during the period 1995-2013. Law 28/2005 and then law 42/2010 prohibited smoking in bars and restaurants as well as playgrounds and access points to schools and hospitals. METHODS: General population data by age and sex were obtained from the National Institute of Statistics census. Data on hospital admissions were obtained from the Minimum Basic Data Set. Diagnoses were codified according to the International Classification of Diseases-9th revision. Data from all hospitals of the Valencian Community from 1995 to 2013 were analysed. Trend analyses in the periods before and after the approval of the 2005 law were conducted using least-squares linear regression models. RESULTS: Adjusted hospital admission rates per 100,000 inhabitants for cardiovascular diseases significantly decreased after the 2005 Law (from 550.0/100,000 in 2005 to 500.5/100,000 in 2007), with a further decrease (to 434.6/100,000) in 2013, after the 2010 Law. Reductions in hospital admissions were seen in men and women, although declining trends were more marked in men. Hospital admission rates for respiratory diseases showed a reduction of a lower magnitude, whereas for smoking-related cancer admissions there was a slight decline only among men. CONCLUSIONS: The Spanish comprehensive smoking ban resulted in a remarkable reduction of the adjusted rate of hospital admissions mainly associated to cardiovascular diseases. The decrease in the number of persons requiring in-patient care is relevant and may be viewed as an improvement of the public's health.


Asunto(s)
Hospitalización/estadística & datos numéricos , Política para Fumadores/legislación & jurisprudencia , Tabaquismo/prevención & control , Tabaquismo/terapia , Adulto , Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/prevención & control , Enfermedades Cardiovasculares/terapia , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fumar/efectos adversos , Prevención del Hábito de Fumar , España/epidemiología , Tabaquismo/epidemiología
3.
Public Health ; 168: 137-141, 2019 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-30769245

RESUMEN

OBJECTIVES: The enhanced safety surveillance for seasonal influenza vaccines established by the European Medicines Agency is required each season. Therefore, a registry capable of rapidly detecting and evaluating potential new safety concerns is needed. The aim of the study is to demonstrate the effectiveness of the vaccine information system of the Valencia region to make a rapid assessment of the influenza vaccine safety and describe the safety of the two vaccine types used in the 2017/2018 season. STUDY DESIGN: It is a population-based descriptive study. METHODS: Adverse events following immunization reports collected from 23rd October 2017 to 15th March 2018 were analyzed. RESULTS: A total of 55 adverse events for influenza vaccine were reported in season 2017/2018 with a reporting rate (RR) of 0.77 per 10,000 administered doses. Injection site reactions had a RR of 0.30 and 0.47 per 10,000 for subunit and adjuvanted vaccines, respectively. Differences per vaccine, sex, and risk group did not reach statistical significance. CONCLUSIONS: Reported events of the two influenza vaccine types used were similar than in other seasons and consistent with their safety profiles.


Asunto(s)
Sistemas de Registro de Reacción Adversa a Medicamentos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , Vacunas contra la Influenza/efectos adversos , Vigilancia de Productos Comercializados , Adolescente , Adulto , Anciano , Niño , Preescolar , Femenino , Humanos , Lactante , Vacunas contra la Influenza/administración & dosificación , Masculino , Persona de Mediana Edad , Sistema de Registros , Factores de Riesgo , Estaciones del Año , España/epidemiología , Adulto Joven
4.
Public Health ; 135: 66-74, 2016 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-26976484

RESUMEN

OBJECTIVES: The surveillance of vaccine safety is an essential requirement in vaccination programmes. Computerized immunization registries such as the Vaccination Information System (SIV) of Valencian Community (Spain) offer the opportunity to estimate the incidence of adverse events according to individual information. The aim of the study was to analyze adverse events following immunization reported through SIV from 2005 to 2011 by age, sex, type of vaccine and dose, and adverse event, and highlight the advantages of this type of reporting. STUDY DESIGN: A retrospective cohort study of subjects vaccinated in the Valencian Community using population health databases was carried out. METHODS: Analysis of vaccinations and reported AEFI via SIV in Valencian Community was carried out. RESULTS: More than 13 million vaccines doses were administered during 2005 through 2011, the reporting rate of adverse events was 12.4/100,000 doses administered with the highest value in 2009 (27.4), with differences by age and sex. DTaP vaccine had the highest reporting in children (96.6/100,000) while influenza A(H1N1)pdm09 in adults (87.7/100,000). An increased reporting of adverse events was seen with DTaP in children 5-6 years of age, detected in real time, drove to swap this vaccine to a low dose Tdap which was followed by a decrease in administration site events. CONCLUSIONS: SIV demonstrates advantages for passive surveillance. Reporting rates by individual characteristics are calculated accurately and it also allows detecting shifts in reporting rate on real time for specific vaccines. The study shows that vaccines included in the routine vaccination schedule for children and adult vaccination programs are safe.


Asunto(s)
Sistemas de Registro de Reacción Adversa a Medicamentos , Vigilancia de Productos Comercializados/métodos , Vacunas/efectos adversos , Adolescente , Adulto , Anciano , Niño , Preescolar , Bases de Datos Factuales , Femenino , Humanos , Lactante , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Seguridad , España , Adulto Joven
5.
J Opt Soc Am A Opt Image Sci Vis ; 30(11): 2237-43, 2013 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-24322920

RESUMEN

Stable and spiral coherent beams, which do not change the form of their intensity distribution apart from possible scaling and rotation during propagation and therefore possess self-healing properties, are widely applied in science and technology. On the other hand, it has been found that partially coherent light often provides better output than coherent light. Here we consider two methods for the design and experimental generation of partially coherent stable and spiral beams.

6.
Opt Express ; 15(25): 16431-41, 2007 Dec 10.
Artículo en Inglés | MEDLINE | ID: mdl-19550933

RESUMEN

We present an analysis of Fourier-transform arrayed waveguide gratings in the Fresnel diffraction regime. We report a distinct spatial modulation of the interference pattern referred to as the Moiré-Talbot effect. The effect and its influence in a FT AWG device is explained by deriving an original analytical expression for the modulated field, and is also confirmed by numerical simulations using the angular spectrum method to solve the Fresnel diffraction integral. We illustrate the retrieval of spectral information in a waveguide Fourier-transform spectrometer in the presence of the Moiré-Talbot effect. The simulated device comprises two interleaved waveguide arrays each with 180 waveguides and the interference order of 40. It is designed with a Rayleigh spectral resolution of 0.1 nm and 8 nm bandwidth at wavelength lambda approximately 1.5 mum. We also demonstrate by numerical simulations that the spectrometer crosstalk is reduced from -20 dB to -40 dB by Gaussian apodization.

7.
Nefrologia ; 26(5): 564-72, 2006.
Artículo en Español | MEDLINE | ID: mdl-17117899

RESUMEN

OBJECTIVE: To evaluate the prevalence of hypertension (HT) in prevalent hemodialysis (HD) patients in our region, and to analyze the associated clinical and biochemical variables. METHODS: Observational, cross-sectional and multicentric study including a representative sample of prevalent and stable (> 6 months) HD patients from all the HD centers (in and out of Hospitals) in Catalonia, Spain. Clinical and biochemical variables were recorded and predialysis blood pressure (BP) was determined (x3) in each dialysis session during 1 month, as well as the pre/post weight weekly. HT was defined as having at least one of these criteria: a mean (12 determinations) systolic BP > or = 140 mmHg or diastolic BP > or = 90 mmHg or antihypertensive treatment for at least 3 months. RESULTS: The sample comprised 387 patients from 32 of the 40 centers included, 231 of whom where men, with mean age of 63 +/- 14 years. The prevalence of HT in this sample was 67.4%, varying according to the etiology of End-Stage Renal Disease: diabetic 81%, vascular 81%, glomerulonephritis 61%, PKD 52%, unknown and others 64%. The prevalence of additional CV risk factors was 83%. One of each hypertensive 4 patients were treated, of whom 58% had systolic BP > or = 140 or dyastolic > or = 90, in contrast to 28% of untreated patients. The proportion of individuals according to the number of antihypertensive agents was 21% (no agents), 48% (1 agent), 20% (2 agents), 11% (3 agents). Blood pressure was higher among patients receiving higher number of antihypertensive agents. No differences according HT were found in age (64 +/- 13 in hypertensive patients versus 60 +/- 15 in normotensives), time on dialysis (4 +/- 4 vs 4 +/- 4 years), interdialysis weight gain (2.1 +/- 0.8 vs 2.1 +/- 0.8 kg), proportion of weight gain (3.3 +/- 1.4 vs 3.1 +/- 1.4%) or proportion of patients with > 5% weight gain with respect to dry weight (32.5 vs 27.3%). While 84% of hypertensive patients had an additional CV risk factor, this value was 67% in the patients without HT (p < 0.001). CONCLUSION: In HD patients HT has a high prevalence in our region and is poorly controlled. The causes of this poor control may be multiple, and weight gain parameters seem not to be a main factor in these stable patients. Due to the aggregation of risk factors in these patients, strategies in order to improve BP control in HD are mandatory.


Asunto(s)
Hipertensión/epidemiología , Diálisis Renal , Anciano , Antihipertensivos/uso terapéutico , Estudios Transversales , Femenino , Humanos , Hipertensión/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Prevalencia , Diálisis Renal/estadística & datos numéricos , Factores de Riesgo , España
8.
Clin Microbiol Infect ; 22(1): 97.e5-97.e8, 2016 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-26408279

RESUMEN

Human respiratory syncytial virus (HRSV) is one of the most common viral aetiological agents in the youngest population. In the present study a novel HRSV-B BA genotype is first described based on the phylogenetic analysis of the coding hypervariable region 2 sequences of G protein from strains detected during the 2014-2015 season. Among all strains detected in the last season, 44% belonged to this new genotype. Therefore, it highlights the importance of a continuous HRSV surveillance to monitor the emergence and spread of new genotypes or variants with genetic changes that may affect antigenic and tropism features.


Asunto(s)
Genotipo , Infecciones por Virus Sincitial Respiratorio/epidemiología , Infecciones por Virus Sincitial Respiratorio/virología , Virus Sincitial Respiratorio Humano/clasificación , Virus Sincitial Respiratorio Humano/aislamiento & purificación , Humanos , Epidemiología Molecular , Filogenia , Virus Sincitial Respiratorio Humano/genética , Análisis de Secuencia de ADN , España/epidemiología , Proteínas del Envoltorio Viral/genética
9.
An Med Interna ; 22(3): 118-23, 2005 Mar.
Artículo en Español | MEDLINE | ID: mdl-15839820

RESUMEN

AIM: To know development pneumonias throughout 1995 to 2001. METHODS: The data source was obtained from the database of the Minimum Basic Data Set. We selected three pneumonia hospitalized causes in the Community of Valencia, Bronchopneumonia, and Pneumonia for not specified organism and invasive pneumococcal disease. It was realized the statistical analysis by SPSS programme. Calculating the pneumonia incidence rate and its time development and observing the interactions between age group, genre, mean of age, stay in the hospital and origin. RESULTS: The incidence for the period was 209 per 100,000 people, that increased significantly until it stabilized in 1999. The pneumonia affected more frequently men than women and specially aged 65 years or more. For age the pneumonias are more frequent in subjects younger than 5 and older than 65, (maximum 76-77 years old). It was observed statistically significant differences between provinces. The stays on hospital was greater for men and this ground with age groups, this is longer in people 65 years old or older. The average stay depending on the aged groups but do not exist statistically differences between genre and age group. CONCLUSIONS: Pneumonia is a pathology originated from different causes, it affect principally men and more especially at younger than 5 years and older than 65 years. The incidences stabilizing on the studied period last years. This works must be continued for clarify if it is the same way for the development by the different pneumonias types on this time period and if exists the interactions between the different variables.


Asunto(s)
Neumonía/epidemiología , Adolescente , Adulto , Distribución por Edad , Anciano , Niño , Preescolar , Infecciones Comunitarias Adquiridas/epidemiología , Femenino , Humanos , Incidencia , Lactante , Masculino , Persona de Mediana Edad , Distribución por Sexo , España/epidemiología
10.
Diabetes Educ ; 25(3): 374-81, 1999.
Artículo en Inglés | MEDLINE | ID: mdl-10531857

RESUMEN

PURPOSE: The purpose of this study was to measure the level of diabetes knowledge in a representative group of Mexican individuals with diabetes and to identify the factors that influence it. METHODS: A validated questionnaire was administered to 570 outpatients; 11.2% had Type 1 diabetes, 36.4% had Type 2 diabetes treated with insulin, and 52.2% had Type 2 diabetes treated with oral agents. Samples for HbA1c determination also were obtained. RESULTS: The percentage of correct answers in each section of the questionnaire was low. Type 1 patients had the highest scores, followed by the insulin-treated Type 2 patients; those with chronic complications also had high scores. Educational background, attendance at diabetes courses, age, and HbA1c concentration were the main predictors of knowledge. Attendance at courses was influenced by the severity of the disease. CONCLUSIONS: The amount of patient knowledge about diabetes-related issues was low in this representative Mexican population. The educational efforts were focused on those with the worst metabolic control and/or with diabetes complications.


Asunto(s)
Diabetes Mellitus/prevención & control , Evaluación Educacional , Conocimientos, Actitudes y Práctica en Salud , Actitud Frente a la Salud , Diabetes Mellitus/sangre , Diabetes Mellitus/psicología , Femenino , Hemoglobina Glucada/análisis , Humanos , Masculino , México , Persona de Mediana Edad , Educación del Paciente como Asunto , Índice de Severidad de la Enfermedad , Encuestas y Cuestionarios
11.
Isr Med Assoc J ; 3(2): 137-43, 2001 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-11344825

RESUMEN

BACKGROUND: Information is lacking on the effects of hormone replacement therapy in women with diabetes, especially during moderate chronic hyperglycemia. OBJECTIVES: To study the effects of HRT on the lipid profile and the low density lipoprotein subclass distribution in women with type 2 diabetes under satisfactory and non-satisfactory glycemic control. METHODS: Fifty-four postmenopausal women after a 6 week run-in diet were randomized to receive either placebo (HbA1c < 8%, n = 13; HbA1c > 8%, n = 17) or HRT (HbA1c < 8%, n = 11; HbA1c > 8%, n = 13) for 12 weeks. HRT consisted of cyclical conjugated estrogens 0.625 mg/day plus medrogestone 5 mg/day. At the beginning and at the end of each treatment period the LDL subclass distribution was estimated by density gradient ultracentrifugation. RESULTS: At the baseline and during the study, the HbA1c level was significantly higher in hyperglycemic patients than in the near-normoglycemic controls (baseline 10.2 +/- 2.9 vs. 6.5 +/- 0.7%, P < 0.01). They showed a trend for higher total and LDL cholesterol, triglycerides and lower high density lipoprotein-cholesterol compared to near-normoglycemic controls, as well as significantly higher triglyceride concentrations in very low density lipoprotein, intermediate density lipoprotein and LDL-1 particles and cholesterol content in LDL-1 and -2 particles. HRT decreased LDL-cholesterol in both groups. In the normoglycemic patients a small increase in HbA1c was observed (6.5 +/- 0.7 vs. 7.4 +/- 1%, P = 0.04). In all cases, HRT did not modify the proportion of LDL represented by denser LDLs. CONCLUSIONS: HRT did not modify the LDL subclass distribution, even in the presence of moderate chronic hyperglycemia in women with type 2 diabetes.


Asunto(s)
Apolipoproteínas B/efectos de los fármacos , Enfermedades Cardiovasculares/prevención & control , Diabetes Mellitus Tipo 2/complicaciones , Estrógenos Conjugados (USP)/administración & dosificación , Terapia de Reemplazo de Hormonas/efectos adversos , Lipoproteínas LDL/efectos de los fármacos , Medrogestona/administración & dosificación , Anciano , Apolipoproteínas B/análisis , Glucemia , Enfermedades Cardiovasculares/etiología , Diabetes Mellitus Tipo 2/diagnóstico , Método Doble Ciego , Femenino , Estudios de Seguimiento , Humanos , Hiperglucemia/diagnóstico , Hiperglucemia/etiología , Lipoproteínas LDL/análisis , Persona de Mediana Edad , Posmenopausia , Probabilidad , Valores de Referencia , Resultado del Tratamiento
12.
Rev Invest Clin ; 53(6): 518-25, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11921524

RESUMEN

BACKGROUND: HbA1c is considered the gold standard of long-term glycemic control and is recommended as a routine test for every diabetic patient. However, its common use in clinical practice has some problems related to lack of standardization and its relative cost. Recent studies have suggested, that postprandial blood glucose could be better than a fasting sample, as a marker of diabetes control. The objective of the present study was to evaluate the relative value of plasma glucose samples at different times of the day, and easy and accessible programs for home blood and urinary glucose measurements compared with HbA1c in assessing the mean glycemic control of type 2 diabetic patients. METHODS: Sixty type 2 diabetic patients were instructed to do home blood and urine glucose monitoring for two months, at the end, plasma glucose profiles were obtained. RESULTS: The mean of all the capillary BG measurements had the best correlation with the HbA1c (r = 0.84, p < 0.001), followed by the mean of the capillary BG measurements before breakfast and supper (r = 0.82, p < 0.001), and the 2 hr. postbreakfast plasma glucose (r = 0.79 p < 0.001). The fasting PG had a low correlation (r = 0.65, p < 0.001), but a good sensitivity to predict a fair or a poor metabolic control. Diabetes duration and type of treatment explained 17% and 28% of variance in HbA1c levels. CONCLUSIONS: A bimonthly fasting PG correlated well with the glycosylated hemoglobin and is the easiest and cheapest way of monitoring glycemic control in type 2 diabetic patients with some preserved insulin reserve (diabetes for less than 10 years and on treatment with only one hypoglycemic agent). A sample of capillary BG, fasting, once per week correlates better with the HbA1c than a fasting PG every 2-3 months. The 2 hr and 5 hr postbreakfast PG have a good correlation with the HbA1c, but are not a substitute for doing BG monitoring. Glycosuria may be a useful parameter to rule out a fair or poor metabolic control in some patients.


Asunto(s)
Glucemia/análisis , Diabetes Mellitus Tipo 2/sangre , Adulto , Anciano , Automonitorización de la Glucosa Sanguínea , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factores de Tiempo
13.
Vaccine ; 32(42): 5447-54, 2014 Sep 22.
Artículo en Inglés | MEDLINE | ID: mdl-25131737

RESUMEN

BACKGROUND: The use of intradermal vaccination or virosomal vaccines could increase protection against influenza among the vulnerable population of older adults. Studies assessing the comparative effectiveness of these two influenza vaccine types in this age group are lacking. METHODS: We conducted a retrospective cohort study to estimate the comparative effectiveness of intradermal seasonal trivalent-influenza vaccine (TIV) delivered by a microneedle injection system and a virosomal-TIV intramuscularly delivered for prevention of influenza hospitalization in non-institutionalized adults aged ≥65 years. We obtained administrative data on immunization status and influenza hospitalization for the 2011-2012 influenza season, and used Cox regression models to assess comparative effectiveness. We estimated crude and adjusted (age, sex, comorbidity, pharmaceutical claims, recent pneumococcal vaccination and number of hospitalizations for all causes other than influenza between the previous and current influenza seasons) hazard ratios (HR). RESULTS: Overall, 164,021 vaccinated subjects were evaluated. There were 127 hospitalizations for influenza among 62,058 subjects, contributing 914,740 person-weeks at risk in the virosomal-TIV group, and 133 hospitalizations for influenza among 101,963 subjects, contributing 1,504,570 person-weeks at risk in the intradermal-TIV group. The crude HR of intradermal-TIV relative to virosomal-TIV was 0.64 (95% confidence interval (CI): 0.50-0.81), and the adjusted Cox estimated HR was 0.67 (95% CI: 0.52-0.85). CONCLUSIONS: During the 2011-2012 influenza season the risk of hospitalization for influenza was reduced by 33% in non-institutionalized elderly adults who were vaccinated with intradermal-TIV compared with virosomal-TIV.


Asunto(s)
Vacunas contra la Influenza/uso terapéutico , Gripe Humana/prevención & control , Anciano , Anciano de 80 o más Años , Femenino , Hospitalización/estadística & datos numéricos , Humanos , Vacunas contra la Influenza/clasificación , Masculino , Modelos de Riesgos Proporcionales , Estudios Retrospectivos , España , Vacunas de Virosoma/uso terapéutico
14.
Vaccine ; 31(37): 3995-4002, 2013 Aug 20.
Artículo en Inglés | MEDLINE | ID: mdl-23731629

RESUMEN

BACKGROUND: Adjuvanted influenza vaccines offer greater and broader immunogenicity to older adults than conventional vaccines. Studies assessing the comparative effectiveness of adjuvanted influenza vaccines in this age group are lacking. METHODS: We conducted a retrospective cohort study to estimate the comparative effectiveness of MF59-adjuvanted trivalent influenza vaccine (TIV) and virosomal-TIV for prevention of influenza hospitalization in adults aged ≥65 years. We obtained administrative data on immunization status and influenza hospitalization for the 2010-2011 influenza season. We used Cox regression models to assess comparative effectiveness; crude and adjusted by age, sex, comorbidity, deprivation, type of insurance, and travel time to hospital. We accounted for data clustering at the hospital level by using a multilevel random effects model. RESULTS: Overall, 373,798 vaccinated subjects were evaluated. There were 40 hospitalizations for influenza among 176,618 subjects, contributing 4,288,109 person-weeks at risk in the virosomal-TIV group, and 37 hospitalizations for influenza among 197,180 subjects, contributing 4,786,360 person-weeks at risk in the MF59-TIV group. The crude hazard ratio (HR) was 0.83 (0.53-1.30), and the adjusted Cox estimated HR of MF59-TIV relative to virosomal-TIV was 0.86 (0.55-1.35). After accounting for data clustering, the HR of influenza hospitalization associated with MF59-TIV relative to virosomal-TIV was 0.94 (0.37-2.38). CONCLUSION: During the 2010-2011 influenza season, we found no differences in the risk of influenza hospitalization in subjects aged ≥65 years vaccinated with MF59-TIV compared with those vaccinated with virosomal-TIV.


Asunto(s)
Adyuvantes Inmunológicos/uso terapéutico , Hospitalización/estadística & datos numéricos , Vacunas contra la Influenza/uso terapéutico , Gripe Humana/prevención & control , Polisorbatos/uso terapéutico , Escualeno/uso terapéutico , Anciano , Anciano de 80 o más Años , Estudios de Cohortes , Comorbilidad , Femenino , Humanos , Vacunas contra la Influenza/inmunología , Gripe Humana/epidemiología , Masculino , Modelos de Riesgos Proporcionales , Estudios Retrospectivos , España , Resultado del Tratamiento , Vacunación/estadística & datos numéricos
15.
Adv Hematol ; 2012: 735392, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22190945

RESUMEN

Background. The outcome of HIV-associated non-Hodgkin lymphoma (NHL) has improved substantially in the highly active antiretroviral therapy (HAART) era. However, HIV-Burkitt lymphoma (BL), which accounts for up to 20% of HIV-NHL, has poor outcome with standard chemotherapy. Patients and Methods. We retrospectively reviewed HIV-BL treated in the HAART era with the Magrath regimen (CODOX-M/IVAC±R) at four Canadian centres. Results. Fourteen patients with HIV-BL received at least one CODOX-M/IVAC±R treatment. Median age at BL diagnosis was 45.5 years, CD4 count 375 cells/mL and HIV viral load (VL) <50 copies/mL. Patients received PCP prophylaxis and G-CSF, 13 received HAART with chemotherapy and 10 rituximab. There were 63 episodes of toxicity, none fatal, including: bacterial infection, n = 20; grade 3-4 hematologic toxicity, n = 14; febrile neutropenia, n = 7; oral thrush; and ifosfamide neurological toxicity, n = 1 each. At a median followup of 11.7 months, 12 (86%) patients are alive and in remission. All 10 patients who received HAART, chemotherapy, and rituximab are alive. CD4 counts and HIV VL 6 months following BL therapy completion (n = 5 patients) were >250 cells/mL and undetectable, respectively, in 4. Conclusion. Intensive chemotherapy with CODOX-M/IVAC±R yielded acceptable toxicity and good survival rates in patients with HIV-associated Burkitt lymphoma receiving HAART.

19.
Phys Rev Lett ; 97(8): 084801, 2006 Aug 25.
Artículo en Inglés | MEDLINE | ID: mdl-17026308

RESUMEN

We report observations of periodic oscillatory behavior of the angular selectivity, near the Bragg angle, in volume holographic gratings recorded in a new photopolymerizable glass with high refractive index modulation. We have detected the presence of overmodulation in the intensity distribution of the first diffraction order. The results reported here were achieved by incorporating in the photopolymerizable sol-gel glass zirconium-based high refractive index species at the molecular level. This is the first time that this effect is observed for light diffraction in an amorphous material.

20.
Diabetes Obes Metab ; 1(1): 29-35, 1999 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-11221809

RESUMEN

OBJECTIVE: To evaluate the efficacy of acarbose in the treatment of secondary failures to sulphonylurea-metformin therapy, its comparison against bedtime NPH insulin, and to measure the changes in postprandial metabolism resulting from both treatments. METHODS: One hundred type 2 diabetic patients in a secondary failure were included. The study begun with a run-in diet period of 6 weeks, in which an isocaloric diet was prescribed. Only subjects who continued hyperglycaemic were randomly assigned to placebo and acarbose (n = 17) or bedtime NPH insulin (n = 12). Acarbose (300 mg/day) or placebo were administered using a randomized, double blind, crossover design. Treatment periods of 3 months were separated by a 3-week washout period. Insulin was administered during 3 months. At the beginning and the end of each treatment period, an i.v. glucose tolerance test and a meal test were performed. Safety tests were done every 4 weeks. RESULTS: Acarbose resulted in a small but significant improvement in fasting plasma glucose (13.5 +/- 2.4 vs. 11.3 +/- 3.9 mmol/l, p = 0.05), HbA1c (11.1 +/- 3.4 vs. 10.3 +/- 2.5%, P = 0.3) and in a decreased plasma glucose during the meal test. Bedtime insulin significantly decreased fasting plasma glucose (13.1 +/- 2.9 vs. 8.2 +/- 2.3 mmol/l, p < 0.01), HbA1c (11.7 +/- 2.9 vs. 9.4 +/- 2.7%, p < 0.01) and plasma cholesterol. No change in insulin secretion resulted from insulin and acarbose treatment. CONCLUSIONS: Acarbose decreases blood glucose in secondary failure to sulphonylurea-metformin therapy; however, the decrease is not enough to reach the desired metabolic control. Bedtime NPH insulin is, by far, a more effective alternative.


Asunto(s)
Acarbosa/uso terapéutico , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipoglucemiantes/uso terapéutico , Insulina Isófana/uso terapéutico , Metformina/uso terapéutico , Compuestos de Sulfonilurea/uso terapéutico , Glucemia/análisis , Ritmo Circadiano , Estudios Cruzados , Diabetes Mellitus Tipo 2/sangre , Método Doble Ciego , Quimioterapia Combinada , Femenino , Humanos , Insulina Isófana/administración & dosificación , Masculino , Persona de Mediana Edad , Periodo Posprandial , Retratamiento , Insuficiencia del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA